MedTrace Logo

Vascular Signature Mapping of Brain Tumor Genotypes

NCT05274919 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2025-03-10

No results posted yet for this study

Summary

A glioma is a primary brain tumor in adults that is characterized by a highly variable, but overall poor survival. The optimal timing of treatment is in part determined by the expected biological behavior of the tumor. At present the expected biological behavior, determined by the tumor genotype, can only be determined by tissue analysis, which requires brain surgery. Non-invasive and improved diagnostic methods are sought to obtain insight into the molecular profile of the tumor and the expected biological behavior to avoid surgery performed solely for diagnostic purposes. Vascularization is an important aspect of the biological behavior of a primary brain tumor. Tumor vascularization characteristics can be assessed by Magnetic Resonance Imaging (MRI), but with the currently available technology this can only be achieved with unacceptably long scan times. In this proposal, the investigators will develop and optimize a novel MRI protocol to gather a large set of quantitative vascularization parameters within an acceptable scan time. The hypothesis is that from such a 'vascular signature' the tumor genotype can be inferred by means of machine learning.

Conditions

Interventions

DEVICE

Philips Achieva 7T MRI

Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.

DEVICE

X-ray (optional)

Optional X-ray scan to assess the safety for undergoing an MR examination.

COMBINATION_PRODUCT

Additional contrast injection

Contrast agent administration for the additional 7T scan (optional).

OTHER

Question list

Questionnaire for contra-indications for an MR examination.

Sponsors & Collaborators

Principal Investigators

  • Matthias JP van Osch, Prof Dr Ir · Leiden University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-16
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05274919 on ClinicalTrials.gov